Stanley Juan Chavez Gutierrez

Dr. Stanley Juan Chavez Gutierrez


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2016 in Molecules
Verified
Journal Article
Open access
PDF file
ONOlívia Azevêdo Nascimento
Olívia Azevêdo Nascimento
RSRenan F. do Espírito Santo
Renan F. do Espírito Santo
LOLuiza Carolina França Opretzka
Luiza Carolina França Opretzka
JFJose Maria Barbosa Filho
Jose Maria Barbosa Filho
SGStanley Juan Chavez Gutierrez
Stanley Juan Chavez Gutierrez
Milena SoaresMilena Soares
Milena Soares
Riparins, natural alkaloids of the alkamide group, can be synthesized by simple methods, enhancing their potential application in pharmaceutical development. Here, the pharmacological properties of riparins were investigated in in vitro and in vivo assays of pain and inflammation in Swiss mice. Inflammatory mediators were measured by radioimmunoassay and Real-Time PCR. Riparins I, II, III and IV (1.56–100 mg/kg; ip) produced dose-related antinociceptive effects in the formalin test, exhibiting ED50 values of 22.93, 114.2, 31.05 and 6.63 mg/kg, respectively. Taking the greater potency as steering parameter, riparin IV was further investigated. Riparin IV did not produce antinociceptive effect on the tail flick, suggesting that its antinociception is not a centrally-mediated action. In fact, riparin IV (1.56–25 mg/kg) produced dose-related antinociceptive and antiedematogenic effects on the complete Freund’s adjuvant (CFA)-induced paw inflammation in mice. During CFA-induced inflammation, riparin IV did not modulate either the production of cytokines, TNF-α and IL-10, or COX-2 mRNA expression. On the other hand, riparin IV decreased the PGE2 levels in the inflamed paw. In in vitro assays, riparin IV did not exhibit suppressive activities in activated macrophages. These results indicate, for the first time, that riparin IV induces antinociceptive and anti-inflammatory effects, possibly through the inhibition of prostanoid production.

13 January 2023 in Future Pharmacology
Verified
Journal Article
Open access
PDF file
MAMaurício Pires de Moura do Amaral
Maurício Pires de Moura do Amaral
MJMarcelo Pereira da Silva Junior
Marcelo Pereira da Silva Junior
FLFrancisco das Chagas Alves Lima
Francisco das Chagas Alves Lima
SGStanley Juan Chavez Gutierrez
Stanley Juan Chavez Gutierrez
Daniel Dias Rufino ArcanjoDaniel Dias Rufino Arcanjo
Daniel Dias Rufino Arcanjo
RORita De Cássia Oliveira
Rita De Cássia Oliveira
Anxiety is a normal behavioral component. When it is too frequent or appears in inappropriate contexts, it can be considered pathological. Benzodiazepines (BDZs) are drugs with clinical success in anxiety treatment. BDZs act as allosteric modulators of the γ- aminobutyric acid A receptor (GABAAR). However, these drugs cause adverse effects. Despite the therapeutic advances obtained with BDZs, the search for anxiolytics with fewer adverse effects is ongoing. Studies with monoterpene (–)-borneol [(–)-BOR] demonstrated pharmacological properties such as a partial agonist effect of GABAAR and an anticonvulsive effect. On the other hand, no work has been developed evaluating the anxiolytic/sedative potential. The objective of this study was to investigate the anxiolytic/sedative effects of (–)-BOR in animal models at doses of 25, 50, and 100 mg/kg (i.p.) and whether there was a molecular interaction with GABAAR. The anxiolytic effect of monoterpene (–)-BOR was tested on Swiss mice (25–30 g) in three anxiety models: the elevated plus maze test, the open field test, and the light-dark box test. The thiopental-induced sleep time model was a drug screen for the sedative and hypnotic activity related to GABAARs. In the molecular docking, the interaction between the GABAAR molecule and (–)-BOR was performed using the AutoDock 4.2.6 program. The results demonstrated that (–)-BOR has sedative and anxiolytic activity. The molecular docking study revealed that (–)-BOR can interact with GABAARs through hydrogen bonds.

27 July 2011 in Fundamental & Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
CMCarla Thiciane Vasconcelos de Melo
Carla Thiciane Vasconcelos de Melo
ACAlyne Mara Rodrigues de Carvalho
Alyne Mara Rodrigues de Carvalho
BMBrinell Arcanjo Moura
Brinell Arcanjo Moura
CTCaroline Porto Leite Teixeira
Caroline Porto Leite Teixeira
LVLeonardo Freire Vasconcelos
Leonardo Freire Vasconcelos
FSFrancisca Cléa Florenço de Sousa
Francisca Cléa Florenço de Sousa

13 May 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
BSB. P. Sousa-Neto
B. P. Sousa-Neto
FCFRANCISCO VALMOR MACEDO CUNHA
FRANCISCO VALMOR MACEDO CUNHA
DNDaniel Barbosa Nunes
Daniel Barbosa Nunes
BGB. S. Gomes
B. S. Gomes
LALayane Valeria Amorim
Layane Valeria Amorim
FOFrancisco Oliveira
Francisco Oliveira
Purpose. To investigate the anti-inflammatory and antioxidant activities of N-salicyloyltryptamine (NST) in experimental models of carrageenan (Cg)-induced peritonitis in mice, and evaluation of the effects of NST on Cg-induced joint disability in rats. Methods. Female Swiss mice were submitted to Cg-induced peritonitis in mice or Cg-induced joint disability in rats after intraperitoneal injection of NST (100 or 200 mg/kg). Total leukocyte count, total protein concentration, myeloperoxidase (MPO) and catalase (CAT) activities, and nitrite () and thiobarbituric acid reactive species (TBARS) levels were determined. Results. NST significantly decrease the migration of leukocytes to peritoneal exudate. Cg induces inflammatory responses mediated by expression of reactive oxygen species (ROS). The results further showed that NST significantly decreased MPO and CAT activities, as well as reduced and TBARS levels, compared with the vehicle group. Animals treated with NST significantly reduced paw elevation time (PET) on the first hour after induction of joint injury, and this effect was sustained throughout the analysis. Conclusion. NST presented anti-inflammatory and antioxidant effects in experimental models of carrageenan-induced peritonitis and joint disability in mice and rats, respectively, which may be related to the modulation of neutrophils migration as well as the involvement of antioxidant mechanisms.

1 January 2023 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
PLPatrícia Virna Sales Leão
Patrícia Virna Sales Leão
AFAna Laura da Silva Ferreira
Ana Laura da Silva Ferreira
FOFelipe Araújo de Alcântara Oliveira
Felipe Araújo de Alcântara Oliveira
AMAvilnete Belém de Souza Mesquita
Avilnete Belém de Souza Mesquita
JNJosé de Sousa Lima Neto
José de Sousa Lima Neto
Josiel FerreiraJosiel Ferreira
Josiel Ferreira
Acinetobacter baumannii is an important opportunistic pathogen that causes serious health‐related infections, especially in intensive care units. The present study aimed to investigate the antimicrobial activity of Riparin‐B (Rip‐B) alone and in association with norfloxacin against multidrug‐resistant clinical isolates of A. baumannii. For this, the minimum inhibitory concentrations were determined by the microdilution method. For the evaluation of resistance‐modulating activity, MIC values for antibiotics were determined in the presence or absence of subinhibitory concentrations of Rip‐B or chlorpromazine (CPZ). The AdeABC‐AdeRS efflux system genes from these isolates were detected by PCR. Docking studies were also carried out to evaluate the interaction of Riparin‐B and the AdeABC‐AdeRS efflux system. The study was conducted from 2017 to 2019. The results showed that Rip‐B showed weak intrinsic activity against the strains tested. On the other hand, Rip‐B was able to modulate norfloxacin’s response against A. baumannii strains that express efflux pump‐mediated resistance. Docking studies provided projections of the interaction between Rip‐B and EtBr with the AdeB protein, suggesting that Rip‐B acts by competitive inhibition with the drug. Results found by in vitro and in silico assays suggest that Rip‐B, in combination with norfloxacin, has the potential to treat infections caused by multidrug‐resistant A. baumanni with efflux pump resistance.

27 April 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
ARAldenora Maria Ximenes Rodrigues
Aldenora Maria Ximenes Rodrigues
RCRayla Kelly Magalhães Costa
Rayla Kelly Magalhães Costa
RMRanyelison Silva Machado
Ranyelison Silva Machado
SGStanley Juan Chavez Gutierrez
Stanley Juan Chavez Gutierrez
FLFrancisco das Chagas Alves Lima
Francisco das Chagas Alves Lima
AOAldeídia Pereira de Oliveira
Aldeídia Pereira de Oliveira
The process involved in the research, discovery and development of drugs is characterized by high extensive and complex cost linked to scientific and technological innovations, and it is necessary to study and verify the progress of research carried out in the field that results in patent applications. Aniba riparia (Nees) Mez is a plant species often used for therapeutic purposes, where its pharmacological properties are associated to the presence of alkaloids called riparins. 5 synthetic analog compounds (riparins A, B, C, D, E and F) were developed from natural riparins. These molecules, natural and synthetic, showed several pharmacological activities in tests performed in vitro and in vivo , highlighting the Central Nervous System (CNS). The objective of this work was to evaluate the physical-chemical, pharmacokinetic parameters (absorption, distribution, metabolism, excretion and toxicity) and pharmacodynamic parameters (bioactivity and adverse reactions) of Riparin B by means of in silico computational prediction. Online software such as Pre-ADMET, SwissADME, Molinspiration and PASS on line were used for the analysis. Riparin B fits the characteristics of druglikeness , pharmacokinetic properties appropriate to the predicted patterns and activities within the scope for the treatment of AD, demonstrating a possible potential in the inhibition of AChE. Therefore, in silico results allow us to conclude that riparin B is predicted to be a potential future drug candidate, especially via oral administration, due to its relevant Drug-likeness profile, bioavailability, excellent liposolubility and adequate pharmacokinetics, including at the level of CNS, penetrating the blood-brain barrier.